HBIO, US4169062043

Harvard Bioscience grows revenue 11.10 percent: what it means for Harvard Bioscience stock

Published on 10/05/2026 at 17:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue rose 11.10 percent to USD 22.70 million in the second quarter of 2026. Harvard Bioscience stock sits at a USD 36.5 million market value.

HBIO, US4169062043, Illustration mit AI erstellt.

Harvard Bioscience (ISIN US4169062043) reported revenue of USD 22.70 million in the second quarter of 2026, up 11.10 percent from USD 20.50 million a year earlier, according to StockTitan on August 11, 2026. The result gives Harvard Bioscience stock a growth story, but the loss and debt load keep the financial picture demanding.

Revenue growth comes with a loss

The company posted a GAAP net loss of USD 2.90 million in the second quarter of 2026, compared with a USD 2.30 million loss in the second quarter of 2025. Diluted loss per share was USD 0.64, while adjusted EBITDA reached USD 1.70 million, up from USD 1.50 million in the prior-year quarter, the filing summary reported by StockTitan said.

For the first six months of 2026, revenue totaled USD 43.50 million, compared with USD 42.20 million in the same period of 2025. GAAP gross margin improved to 57.20 percent from 56.20 percent, while operating cash flow was negative USD 0.30 million compared with positive USD 5.70 million a year earlier.

What the growth means

The operating contrast matters: revenue expanded by USD 2.20 million in the first half of 2026, yet cash generation moved lower by USD 6.00 million year over year. That combination places greater weight on the company's cost controls and recurring-revenue strategy.

Harvard Bioscience reported 54.00 percent recurring revenue for fiscal year 2025 and described a path toward 60.00 percent or more. The company also outlined Project Viking, a manufacturing consolidation expected to add USD 3.00 million to adjusted EBITDA in 2027 and USD 4.00 million annually from 2028, according to StockTitan.

Debt sets the financial limit

At June 30, 2026, cash and cash equivalents stood at USD 6.50 million against USD 36.70 million of debt, while stockholders' equity was USD 7.40 million. The balance sheet therefore remains a central counterweight to the second-quarter sales increase, particularly as the company carries high financing costs.

Market value and trading range

Harvard Bioscience had a market capitalization of USD 36.5 million and a 52-week range of USD 3.75 to USD 9.40 as of September 24, 2026. Its next earnings date was listed as November 5, 2026, giving the next quarterly report a clear test of revenue growth, cash generation and the Project Viking savings plan.